On 12 March 2015, BPI publisher Brian Caine and editor in chief Anne Montgomery spoke with Harvey Brandwein, Pall’s vice president of business development, at the company’s Port Washington, NY, facility. Pall’s director of marketing for cell therapies, Alain Fairbank, also provided her thoughts on the evolution of tools and technologies for this market sector.

Knowing that this interview would become one of the concluding chapters in Pall’s special issue with BPI, we reviewed a number of topics covered earlier, asking Brandwein to comment about how all these elements need to come together to advance the business case for cell-based therapies. We began by asking him about his responsibilities at Pall and how his experiences in the broader biotechnology industry have shaped his perspectives.

Read the full text of this article in the PDF (Login required).